Inventory turnover of Alector, Inc. – HAN:0Z2
The article focuses on the inventory turnover of Alector, Inc. (HAN:0Z2), a biotechnology company listed on the Hannover Stock Exchange. It provides financial data related to the inventory turnover for different periods, though specific values are not detailed in the provided text.
Total operating expenses of Alector, Inc. – HAN:0Z2
This article provides a brief overview of Alector, Inc.'s total operating expenses, listed under the ticker HAN:0Z2 on the Hannover Stock Exchange. The current market status shows no trades. The content highlights the financial data available for the company.
Net income of Alector, Inc. – HAN:0Z2
This article provides financial information for Alector, Inc. (0Z2) listed on the Hannover Stock Exchange. It focuses on the net income of the company and appears to be a stub or data-only page from TradingView, indicating that specific financial data would be presented for different periods.
Biotechnology Value Fund group discloses 8.4% stake in Alector (ALEC)
The Biotechnology Value Fund (BVF) group, including affiliated entities and Mark N. Lampert, has reported an 8.4% passive beneficial stake in Alector, Inc. (ALEC) common stock. This stake represents 9,374,267 shares out of 111,656,919 shares outstanding as of July 31, 2026. The filing indicates shared voting and dispositive power among the reporting persons and their various entities.
Alector at Morgan Stanley conference: reset centers on brain delivery
Alector (ALEC) announced a strategic shift at the Morgan Stanley Global Healthcare Conference, moving from a late-stage clinical company to a pre-clinical developer focused on its Alector Brain Carrier (ABC) platform. This pivot preserves its neurodegenerative disease mission despite setbacks in earlier approaches, with new programs targeting Alzheimer's, Parkinson's, and Lewy body dementia, supported by $170 million in cash projected to fund operations through 2027. The company emphasizes its de-risked portfolio based on human genetics and strong non-human primate data, with the lead asset AL137 expected to begin human dosing in Q2 2027.
Alector at Morgan Stanley conference: reset centers on brain delivery By Investing.com
Alector announced a strategic reset at the Morgan Stanley conference, shifting from a late-stage clinical company to a pre-clinical developer focused on its Alector Brain Carrier (ABC) platform for neurodegenerative diseases. The company plans to start dosing healthy volunteers for its lead asset, AL137, in Q2 2027 and believes its $170 million cash balance will fund operations through 2027 into proof-of-concept readouts. Alector emphasized its use of AI for efficiency, retention of core R&D capabilities, and potential partnerships for specific assets, while committing to advance AL137 independently through clinical proof of concept.
Don't Ignore The Insider Selling In Alector
Alector Co-Founder, Arnon Rosenthal, recently sold US$193k worth of shares, though this was only 1.2% of his holding. While the sale occurred at the current stock price, which is not as concerning as a lower-priced sale, there has been no insider buying in the last year, suggesting caution. Insiders own 6.6% of Alector shares, valued at US$18m.
ALEC: Alector Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Alector Inc. (ALEC), a clinical-stage biopharmaceutical company focusing on immuno-neurology. It includes current stock price, market capitalization, key financial metrics, recent news, and investor sentiment. The company aims to develop treatments for degenerative brain disorders by repairing genetic mutations and rejuvenating immune cells.
Alector | 4: Statement of changes in beneficial ownership of securities-Officer Rosenthal Arnon
This article is a statement of changes in beneficial ownership of securities for Officer Rosenthal Arnon of Alector. The content simply states "Document," indicating that the full details are likely contained within a linked or attached document.
Alector CEO Arnon Rosenthal sells $193,473 in stock
Alector CEO Arnon Rosenthal sold 72,606 shares of Alector, Inc. stock for a total of $193,473 on September 3, 2026. The sale was made to cover tax obligations from vested restricted stock units. Despite the stock being up 58% year-to-date, InvestingPro analysis indicates the company may be overvalued relative to its fair value.
Alector CFO Neil Berkley sells $77,948 of ALEC shares
Alector CFO Neil Berkley sold 29,251 shares of ALEC stock for a total of $77,948 to cover tax obligations from vested restricted stock units. Following the sale, Berkley still holds 350,649 shares. InvestingPro analysis suggests the stock is overvalued despite the company's strong cash position.
Alector’s Grace Wong-Sarad sells $24,665 in shares
Grace Wong-Sarad, Principal Accounting Officer at Alector, Inc. (NASDAQ:ALEC), sold 9,446 shares of company stock in early September across three transactions, totaling approximately $24,665. The sales were made pursuant to a Rule 10b5-1 trading plan and to cover tax obligations. Following these transactions, Ms. Wong-Sarad beneficially owns 106,015 shares of Alector common stock, as the company's shares have seen a 58% year-to-date surge.
Alector CEO Arnon Rosenthal sells $193,473 in stock By Investing.com
Alector, Inc. CEO Arnon Rosenthal sold 72,606 shares of company stock for a total of $193,473 on September 3, 2026. The sale was executed to cover tax obligations from vested restricted stock units. Following the transaction, Rosenthal retains significant direct and indirect ownership in the company.
Alector (NASDAQ: ALEC) officer lines up another stock sale
Alector, Inc. officer Grace Wong-Sarad has filed a Rule 144 notice to sell 3,625 restricted common shares of ALEC, valued at $9,094.40. This filing also discloses previous sales by Wong-Sarad in the past three months, including 5,165 shares on September 3, 2026, and 656 shares on September 2, 2026, which are relevant for Rule 144 volume calculations. The proposed sale is scheduled for September 1, 2026.
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc., a biotechnology company specializing in neurodegenerative diseases, announced its participation in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will host fireside chats at both events, which will be webcast live and available for replay on the company's investor relations website. Alector is focused on developing therapies using genetics, immunology, and neuroscience principles to address conditions like Alzheimer's and Parkinson's diseases.
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (Nasdaq: ALEC) announced its participation in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will hold fireside chats at both events, which will be webcast live on the company's investor relations website. Alector is a biotechnology company focused on developing therapies for neurodegenerative diseases.
Alector (ALEC) CFO sells stock to cover RSU tax bill
Alector's CFO & Chief Business Officer, Berkley Neil Lindsay, sold 29,251 shares of ALEC common stock on September 3, 2026, at a weighted average price of $2.6648 per share. This sale was conducted to cover tax obligations arising from the vesting of restricted stock units (RSUs). Following this transaction, Lindsay directly holds 350,649 shares of Alector common stock, and the sale was not made under a Rule 10b5-1 trading plan.
Alector (ALEC) Q1 2025 Earnings: Results, Market Reaction & History
Alector (ALEC) reported mixed Q1 2025 earnings, with an EPS of $-0.41 beating estimates, but revenue of $3.67 million falling short due to the wind-down of collaboration obligations. The company is advancing its neurodegenerative disease pipeline, with key topline data from the INFRONT-3 Phase 3 trial expected in Q4 2025, and maintains a cash runway into the second half of 2027.
Alector (ALEC) Earnings History & Trends
This article provides an overview of Alector Inc.'s (ALEC) earnings history and trends, including EPS and revenue comparisons against Street estimates. It highlights a 100% EPS beat rate and an average EPS surprise of +28.53%. The report also includes detailed quarterly data for EPS and revenue, along with their respective surprises.
Alector (ALEC) CEO shifts 2.1M shares into family trusts
Alector, Inc. (ALEC) CEO Arnon Rosenthal transferred 2.1 million shares of common stock among family trusts on August 19, 2026, as reported in a Form 4 filing. The shares were gifted from The Rosenthal Family Revocable Trust to three separate 2007 family trusts at a reported price of $0.0000 per share. After these transactions, Rosenthal directly holds 2,367,206 shares, with additional indirect holdings through the trusts where he serves as trustee.
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages
Alector, Inc. (NASDAQ:ALEC) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $3.625 against a current share price of $2.15. Despite beating quarterly earnings expectations with a smaller loss and higher revenue, the company remains deeply unprofitable, with analysts forecasting continued losses. Insider selling and institutional investment adjustments were also noted.
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%
Analysts have significantly upgraded their near-term revenue forecasts for Alector, Inc. by 60%, pushing the consensus for 2026 revenues to US$11m, despite an expected 21% reduction in sales over the past 12 months. While losses per share are still expected, analysts reduced their loss estimates, indicating increased optimism. The stock has already seen a 36% increase, and it remains to be seen if this upgrade will further propel its value.
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60%
Analysts have significantly upgraded Alector, Inc.'s near-term revenue forecasts by 60%, with the consensus for 2026 now standing at US$11 million, despite an expected 21% reduction in sales over the past year. While losses per share are predicted to decrease by 19% to US$0.86, analysts anticipate Alector's revenue decline to accelerate faster than the wider industry. This positive sentiment from the revenue upgrade has coincided with a 36% rise in Alector's stock price over the past week.
TD Cowen Maintains Alector(ALEC.US) With Hold Rating
TD Cowen has reiterated its Hold rating on Alector (ALEC.US). The report indicates the firm's continued assessment of Alector's stock.
HC Wainwright Issues Negative Outlook for Alector Earnings
HC Wainwright has lowered its Q3 and full-year 2026 earnings estimates for Alector, forecasting a deeper loss per share despite the company beating revenue expectations in its latest quarterly results. Alector's stock opened down 5.1% at $1.69, and analysts currently hold a consensus "Hold" rating with an average price target of $3.62. Institutional investors own a significant 85.83% of the shares, while recent insider activity shows sales by the CEO and CFO.
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Announces Target Price $1
BofA Securities has reiterated its Sell rating for Alector (ALEC.US) and set a target price of $1.00. This analyst action reflects a continued bearish outlook on the company's stock by the firm.
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)
Analysts have provided insights on several healthcare companies, including Alector (ALEC), Genmab (GMAB), and Xenon (XENE). Alector received a Hold rating from William Blair, with a consensus Hold rating and a significant upside potential. Genmab was rated Buy by TD Cowen and TipRanks – PerPlexity, maintaining a Strong Buy consensus with a solid upside. Xenon also received a Buy rating from TD Cowen and TipRanks – DeepSeek, leading to a Strong Buy consensus among analysts.
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE)
Analysts from William Blair and TD Cowen have provided insights on several healthcare companies. Alector (ALEC) received a Hold rating from Myles Minter of William Blair, with a general analyst consensus also at Hold. Genmab (GMAB) was maintained as a Buy by Yaron Werber from TD Cowen, reflecting a Strong Buy consensus, while Xenon (XENE) also received a maintained Buy rating from Joseph Thome of TD Cowen, with a Strong Buy consensus.
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright has reiterated its Buy rating for Alector (ALEC.US) and maintained its target price at $5. This indicates continued confidence from the analyst firm in the company's prospects.
Alector Inc (ALEC) Stock News Today
This article provides current stock news for Alector Inc (ALEC), a biotechnology and medical research company. As of the closing bell on August 7th, ALEC stock was trading at $1.780 USD, down 2.73%. The page indicates that more news regarding earnings, analyst ratings, and key developments will be available soon.
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Alector Inc (ALEC) has an earnings forecast score of 6.50, ranking 325 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $1.50, with a high of $5.00 and a low of $0.75, predominantly recommending a "Hold" for the stock. The company's expected revenue for the next quarter is $2.41M, and its previous quarter's EPS matched market expectations at -$0.21, with the next quarter's EPS projected at -$0.23.
Alector, Inc. 2Q 2026: Revenue $3.32M, EPS $(0.21) — 10-Q Summary
Alector, Inc. reported its second-quarter 2026 results, showing a revenue of $3.32 million, a 57.8% decline year-over-year, and a net loss of $23 million, an improvement from the $30.5 million loss in the prior year. Diluted EPS improved to $(0.21) from $(0.30) YoY. The company is advancing its pipeline with AL137, while GSK discontinued a collaboration, leading to program wind-downs.
Alector, Inc. (ALEC) Stock Price, News, Quote & History
This page provides comprehensive financial data, news, and analysis for Alector, Inc. (ALEC), a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. It includes real-time stock price information, historical performance, key statistics, analyst ratings, and a company overview detailing its pipeline of investigational treatments. The company's stock closed at $1.83, up 22.82%, with a pre-market price of $1.84.
Alector earnings beat by $0.02, revenue topped estimates
Alector (NASDAQ: ALEC) reported better-than-expected Q2 earnings, with an EPS of $-0.21 against an analyst estimate of $-0.23, and revenue of $3.32M, surpassing the consensus of $2.12M. Despite the positive earnings, the company's stock has seen a -11.43% decline in the last three months, though it is up 27.40% over the past year. InvestingPro notes Alector's financial health as "weak performance".
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector, Inc. reported its second-quarter 2026 financial results, highlighting $172.8 million in cash, cash equivalents, and investments, projected to fund operations through 2027. The company is advancing its Alector Brain Carrier (ABC) platform, with AL137 for Alzheimer's disease targeting an IND submission in Q1 2027, and continued progress in other neurodegenerative programs like AL064/AL164 for tauopathies and AL050 for Parkinson's disease. Alector's net loss for the quarter was $23.0 million, an improvement from $30.5 million in the same period last year, driven by reduced R&D and G&A expenses.
Alector Inc expected to post a loss of 23 cents a share - Earnings Preview
Alector Inc (ALEC) is projected to report a loss of 23 cents per share. This earnings preview suggests analysts are anticipating a negative financial outcome for the company in its upcoming report.
ALEC|Alector Inc|Price:1.510|Chg%:-0.110
This article provides a detailed financial overview of Alector Inc. (ALEC), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and balance sheet details. It also includes an analyst rating of "HOLD" and answers frequently asked questions regarding the company's financial performance in FY2025.
Alector Inc (0Z2) Q4 2022 Earnings Report - Results, Call & Slides
Alector Inc (0Z2) released its Q4 2022 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -€0.55 against a consensus of -€0.40 and actual revenue of €12.52M compared to an expected €26.13M. Alector's next earnings date is estimated for November 10, 2026.
Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC
This article provides a financial snapshot for Alector, Inc. (NASDAQ: ALEC), focusing on its enterprise value to EBITDA forward. It details that the market for Alector, Inc. is currently closed with no trades. The content is primarily a data presentation from TradingView, with disclaimers about market and reference data providers.
Alector Inc (0Z2) Q4 2023 Earnings Report - Results, Call & Slides
Alector Inc (0Z2) reported its Q4 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -€0.42 against a consensus of -€0.67, and actual revenue of €13.17M versus an expected €7.66M, representing a YoY revenue growth of +5.19%. The earnings call took place on February 27, 2024, and the next earnings report is estimated for November 10, 2026.
Alector (ALEC) Expected to Post Quarterly Earnings on Thursday
Alector (ALEC) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th, with analysts forecasting a loss of $0.24 per share and revenue of $1.43 million. This follows a Q1 report where the company beat EPS estimates but significantly missed revenue expectations. Despite a consensus "Hold" rating, analysts project full-year losses of approximately $1 per share, and recent insider selling has also been noted.
ALEC|Alector Inc|Price:1.640|Chg%:+0.120
Alector Inc (ALEC) has received an overall TradingKey Stock Score of 5.79/10, indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued. Institutional ownership is very high, and analysts have recently rated the stock as "Hold" with a target price of $3.10. The company, a clinical-stage biotechnology firm focused on neurodegenerative diseases, is in a growing phase but faces risks such as being overvalued and institutional selling.
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis
This article analyzes the valuation of Alector Inc (ALEC), noting its current valuation score of 6.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.28 and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The analysis provides key financial metrics and a brief overview of Alector Inc's market performance.
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Alector Inc (ALEC), listing major shareholders and their proportional holdings, as well as the types of shareholders. It also provides a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over recent quarters. The report concludes with a list of ETFs related to Alector Inc and their proportional holdings.
Alector Inc (ALEC) Cash Flow Statement
This article provides Alector Inc's (ALEC) cash flow statements, including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and free cash flow, explaining their importance for evaluating a company's financial health, with specific figures for Alector Inc's latest quarter and fiscal year.
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Alector Inc (ALEC), noting that relevant data regarding business segments, regional revenue, and profit contribution has not yet been disclosed by the company. It briefly presents the stock’s current trading information, including its market cap and recent price movements. The page serves as a placeholder for detailed financial analysis that is currently unavailable.
ALEC|Alector Inc|Price:1.520|Chg%:+0.040
Alector Inc. (ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's pipeline includes latozinemab and AL101/GSK4527226, targeting progranulin levels, and several preclinical candidates utilizing its ABC blood-brain barrier platform. ALEC's stock information, executive team, and institutional ownership details are provided, showing a market cap of 168.76M.
ALEC|Alector Inc|Price:1.480|Chg%:-0.010
Alector Inc (ALEC) is a clinical-stage biotechnology company focused on neurodegenerative diseases. The stock is currently trading at $1.480, down 0.67%, with a market capitalization of $164.32 million. Analysts rate the stock as "Hold" with a target price of $3.10, suggesting a potential upside of 108.05%.
Spruce Street Capital LP Buys 983,082 Shares of Alector, Inc. $ALEC
Spruce Street Capital LP significantly increased its stake in Alector, Inc. (NASDAQ:ALEC) by 87.9% in the first quarter, purchasing an additional 983,082 shares to bring its total holding to over 2.1 million shares, representing about 1.89% of the company. Alector's stock recently traded down 0.7% to $1.48, well below its 52-week high, despite beating EPS expectations but falling short on revenue. Analysts currently maintain a consensus "Hold" rating with an average price target of $3.62 for the clinical-stage biotechnology company.
Alector, Inc. Revenue Breakdown – NASDAQ:ALEC
Alector, Inc. (NASDAQ:ALEC) generated $21.05 million USD in revenue last year, primarily from its Immuno-neurology segment. This figure is a decrease from the previous year's $100.56 million USD. The United States was the company's largest contributor to revenue.
